Drug Consortium Offers $50M for Collective Research
MarketWatch website reports that the Takeda Pharmaceutical Company has joined the Structural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new, more effective medicines to market faster. Takeda’s contribution raises the total to $50 million in support of the SGC by six of the world’s leading pharmaceutical companies engaged in drug discovery, bolstering this ground-breaking pre-competitive approach to drug research.
Click here to read the full article.